Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non Operating Income: 2019-2024

Historic Other Non Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $4.2 million.

  • Foghorn Therapeutics' Other Non Operating Income fell 49.80% to $620,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 24.16%. This contributed to the annual value of $4.2 million for FY2024, which is 47.05% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Other Non Operating Income of $4.2 million as of FY2024, which was up 47.05% from $2.8 million recorded in FY2023.
  • Foghorn Therapeutics' Other Non Operating Income's 5-year high stood at $4.2 million during FY2024, with a 5-year trough of $1.0 million in FY2020.
  • Over the past 3 years, Foghorn Therapeutics' median Other Non Operating Income value was $2.8 million (recorded in 2023), while the average stood at $3.2 million.
  • Data for Foghorn Therapeutics' Other Non Operating Income shows a peak YoY spiked of 149.15% (in 2021) over the last 5 years.
  • Foghorn Therapeutics' Other Non Operating Income (Yearly) stood at $1.0 million in 2020, then skyrocketed by 149.15% to $2.5 million in 2021, then rose by 3.45% to $2.6 million in 2022, then increased by 9.73% to $2.8 million in 2023, then soared by 47.05% to $4.2 million in 2024.